clinical trial · NCT06025110
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
Diabetes Mellitus, Type 1TCD601Placebo
brief summary
The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.
started
Jan 23, 2023
primary completion
Jul 24, 2025
completion
Jul 24, 2025
last updated
Aug 14, 2025
official title
A 12-month, Randomized, Single-blind, Placebo-controlled Exposure-response Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients (STRIDE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol